TY - JOUR
T1 - Monoclonal Gammopathy–Associated Peripheral Neuropathy
T2 - Diagnosis and Management
AU - Chaudhry, Hafsa M.
AU - Mauermann, Michelle L.
AU - Rajkumar, S. Vincent
N1 - Funding Information:
Grant Support: This work was supported in part by grants CA186781, CA 107476, and CA 168762 from the National Cancer Institute.
Publisher Copyright:
© 2017 Mayo Foundation for Medical Education and Research
PY - 2017/5
Y1 - 2017/5
N2 - Monoclonal gammopathies comprise a spectrum of clonal plasma cell disorders that include monoclonal gammopathy of undetermined significance, multiple myeloma, and Waldenström macroglobulinemia. In this review, we outline the epidemiology, etiology, classification, diagnosis, and treatment of monoclonal gammopathy–associated peripheral neuropathy. Monoclonal gammopathy of undetermined significance is relatively common in the general population, with a prevalence of 3% to 4% among individuals older than age 50 years. Therefore, the presence of M protein in a patient with neuropathy does not automatically indicate a causal relationship. Monoclonal gammopathy–associated peripheral neuropathy is often a difficult diagnosis with limited treatment options. Studies addressing the optimal approach to diagnosis and management of this entity are limited. In addition to a review of the literature, we present a diagnostic approach to patients with monoclonal gammopathy–associated peripheral neuropathy and discuss available data and options for treatment.
AB - Monoclonal gammopathies comprise a spectrum of clonal plasma cell disorders that include monoclonal gammopathy of undetermined significance, multiple myeloma, and Waldenström macroglobulinemia. In this review, we outline the epidemiology, etiology, classification, diagnosis, and treatment of monoclonal gammopathy–associated peripheral neuropathy. Monoclonal gammopathy of undetermined significance is relatively common in the general population, with a prevalence of 3% to 4% among individuals older than age 50 years. Therefore, the presence of M protein in a patient with neuropathy does not automatically indicate a causal relationship. Monoclonal gammopathy–associated peripheral neuropathy is often a difficult diagnosis with limited treatment options. Studies addressing the optimal approach to diagnosis and management of this entity are limited. In addition to a review of the literature, we present a diagnostic approach to patients with monoclonal gammopathy–associated peripheral neuropathy and discuss available data and options for treatment.
UR - http://www.scopus.com/inward/record.url?scp=85018386672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018386672&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2017.02.003
DO - 10.1016/j.mayocp.2017.02.003
M3 - Review article
C2 - 28473042
AN - SCOPUS:85018386672
SN - 0025-6196
VL - 92
SP - 838
EP - 850
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 5
ER -